JP7360440B2 - Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子 - Google Patents

Info

Publication number

JP7360440B2

JP7360440B2 JP2021500385A JP2021500385A JP7360440B2 JP 7360440 B2 JP7360440 B2 JP 7360440B2 JP 2021500385 A JP2021500385 A JP 2021500385A JP 2021500385 A JP2021500385 A JP 2021500385A JP 7360440 B2 JP7360440 B2 JP 7360440B2

Authority

JP

Japan

Prior art keywords

antibody molecule

seq

domain

antibody

human

Prior art date

2018-07-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 title claims description 437
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 title claims description 396
• 108010074708 B7-H1 Antigen Proteins 0.000 title claims description 390
• 102000008096 B7-H1 Antigen Human genes 0.000 title claims 5
• 210000004027 cell Anatomy 0.000 claims description 333
• 230000027455 binding Effects 0.000 claims description 271
• 206010028980 Neoplasm Diseases 0.000 claims description 156
• 239000000427 antigen Substances 0.000 claims description 138
• 108091007433 antigens Proteins 0.000 claims description 136
• 102000036639 antigens Human genes 0.000 claims description 136
• 201000011510 cancer Diseases 0.000 claims description 66
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 62
• 238000000034 method Methods 0.000 claims description 58
• 238000011282 treatment Methods 0.000 claims description 58
• 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 claims description 56
• 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims description 56
• 150000007523 nucleic acids Chemical class 0.000 claims description 50
• 108010073807 IgG Receptors Proteins 0.000 claims description 40
• 102000009490 IgG Receptors Human genes 0.000 claims description 38
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 30
• 210000002865 immune cell Anatomy 0.000 claims description 28
• 239000013598 vector Substances 0.000 claims description 28
• 102000039446 nucleic acids Human genes 0.000 claims description 27
• 108020004707 nucleic acids Proteins 0.000 claims description 27
• 125000000539 amino acid group Chemical group 0.000 claims description 18
• 238000004519 manufacturing process Methods 0.000 claims description 17
• 210000004881 tumor cell Anatomy 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
• 238000012258 culturing Methods 0.000 claims description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 387
• 210000001744 T-lymphocyte Anatomy 0.000 description 185
• 241000282414 Homo sapiens Species 0.000 description 157
• 238000003556 assay Methods 0.000 description 126
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 123
• 230000000694 effects Effects 0.000 description 102
• 230000006044 T cell activation Effects 0.000 description 85
• 239000013641 positive control Substances 0.000 description 78
• 241000282567 Macaca fascicularis Species 0.000 description 61
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 60
• 102000048776 human CD274 Human genes 0.000 description 59
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 52
• 230000004913 activation Effects 0.000 description 52
• 238000004132 cross linking Methods 0.000 description 52
• 230000014509 gene expression Effects 0.000 description 51
• 239000000872 buffer Substances 0.000 description 49
• 230000002998 immunogenetic effect Effects 0.000 description 49
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 45
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 45
• 108090000623 proteins and genes Proteins 0.000 description 43
• 241000699666 Mus <mouse, genus> Species 0.000 description 40
• 235000018102 proteins Nutrition 0.000 description 40
• 102000004169 proteins and genes Human genes 0.000 description 40
• 102000050327 human TNFRSF9 Human genes 0.000 description 39
• 230000035772 mutation Effects 0.000 description 34
• 230000004044 response Effects 0.000 description 34
• 108010002350 Interleukin-2 Proteins 0.000 description 31
• 102000000588 Interleukin-2 Human genes 0.000 description 31
• 238000005516 engineering process Methods 0.000 description 31
• 241000699670 Mus sp. Species 0.000 description 29
• 150000001413 amino acids Chemical class 0.000 description 29
• 235000001014 amino acid Nutrition 0.000 description 28
• 229940024606 amino acid Drugs 0.000 description 27
• 239000002609 medium Substances 0.000 description 27
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 26
• 239000000556 agonist Substances 0.000 description 25
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 25
• 239000000203 mixture Substances 0.000 description 25
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 25
• 108091028043 Nucleic acid sequence Proteins 0.000 description 24
• 239000013642 negative control Substances 0.000 description 24
• 238000012512 characterization method Methods 0.000 description 23
• 238000012360 testing method Methods 0.000 description 23
• 102000004127 Cytokines Human genes 0.000 description 21
• 108090000695 Cytokines Proteins 0.000 description 21
• 108010074328 Interferon-gamma Proteins 0.000 description 21
• 230000000903 blocking effect Effects 0.000 description 20
• 230000001965 increasing effect Effects 0.000 description 20
• 102000005962 receptors Human genes 0.000 description 20
• 108020003175 receptors Proteins 0.000 description 20
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 19
• 238000004458 analytical method Methods 0.000 description 19
• 238000000684 flow cytometry Methods 0.000 description 18
• 238000003780 insertion Methods 0.000 description 18
• 230000037431 insertion Effects 0.000 description 18
• 102100037850 Interferon gamma Human genes 0.000 description 17
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 17
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
• 238000002965 ELISA Methods 0.000 description 16
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
• 239000012091 fetal bovine serum Substances 0.000 description 16
• 238000006467 substitution reaction Methods 0.000 description 16
• 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 15
• 238000010790 dilution Methods 0.000 description 15
• 239000012895 dilution Substances 0.000 description 15
• 108090000765 processed proteins & peptides Proteins 0.000 description 15
• 238000012216 screening Methods 0.000 description 15
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 14
• 238000002835 absorbance Methods 0.000 description 14
• 239000006143 cell culture medium Substances 0.000 description 14
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
• 239000003814 drug Substances 0.000 description 14
• 230000003993 interaction Effects 0.000 description 14
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 14
• 239000006228 supernatant Substances 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 108010057466 NF-kappa B Proteins 0.000 description 13
• 102000003945 NF-kappa B Human genes 0.000 description 13
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 13
• 230000036515 potency Effects 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 13
• 230000009260 cross reactivity Effects 0.000 description 12
• 230000002401 inhibitory effect Effects 0.000 description 12
• 230000003389 potentiating effect Effects 0.000 description 12
• 230000004614 tumor growth Effects 0.000 description 12
• 229940116741 CD137 agonist Drugs 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
• 230000008484 agonism Effects 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000005714 functional activity Effects 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• 230000004083 survival effect Effects 0.000 description 11
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
• 241001529936 Murinae Species 0.000 description 10
• 125000003275 alpha amino acid group Chemical group 0.000 description 10
• 210000003719 b-lymphocyte Anatomy 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 230000028993 immune response Effects 0.000 description 10
• 238000001542 size-exclusion chromatography Methods 0.000 description 10
• 206010006187 Breast cancer Diseases 0.000 description 9
• 239000004971 Cross linker Substances 0.000 description 9
• 108010021468 Fc gamma receptor IIA Proteins 0.000 description 9
• 239000004471 Glycine Substances 0.000 description 9
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 9
• 108060003951 Immunoglobulin Proteins 0.000 description 9
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 9
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
• 230000001270 agonistic effect Effects 0.000 description 9
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 9
• 238000010494 dissociation reaction Methods 0.000 description 9
• 230000005593 dissociations Effects 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 9
• 102000018358 immunoglobulin Human genes 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 238000002823 phage display Methods 0.000 description 9
• 230000000717 retained effect Effects 0.000 description 9
• 230000019491 signal transduction Effects 0.000 description 9
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 9
• 229950005972 urelumab Drugs 0.000 description 9
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 8
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 8
• 230000000259 anti-tumor effect Effects 0.000 description 8
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 230000006240 deamidation Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 108010068617 neonatal Fc receptor Proteins 0.000 description 8
• 238000004806 packaging method and process Methods 0.000 description 8
• 238000001959 radiotherapy Methods 0.000 description 8
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 238000004448 titration Methods 0.000 description 8
• 208000026310 Breast neoplasm Diseases 0.000 description 7
• 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 7
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
• 239000012515 MabSelect SuRe Substances 0.000 description 7
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 7
• 230000003213 activating effect Effects 0.000 description 7
• 235000004279 alanine Nutrition 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 235000020958 biotin Nutrition 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 239000002299 complementary DNA Substances 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 210000004443 dendritic cell Anatomy 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 230000036541 health Effects 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 210000001616 monocyte Anatomy 0.000 description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
• 206010005003 Bladder cancer Diseases 0.000 description 6
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 6
• 108060001084 Luciferase Proteins 0.000 description 6
• 239000005089 Luciferase Substances 0.000 description 6
• 206010033128 Ovarian cancer Diseases 0.000 description 6
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 6
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000009824 affinity maturation Effects 0.000 description 6
• 238000012575 bio-layer interferometry Methods 0.000 description 6
• 239000011616 biotin Substances 0.000 description 6
• 229960002685 biotin Drugs 0.000 description 6
• 230000005907 cancer growth Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 210000000987 immune system Anatomy 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 210000000265 leukocyte Anatomy 0.000 description 6
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
• 201000002528 pancreatic cancer Diseases 0.000 description 6
• 102000004196 processed proteins & peptides Human genes 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
• 201000005112 urinary bladder cancer Diseases 0.000 description 6
• 229950003520 utomilumab Drugs 0.000 description 6
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
• 238000011740 C57BL/6 mouse Methods 0.000 description 5
• 101150013553 CD40 gene Proteins 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• 229920001917 Ficoll Polymers 0.000 description 5
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
• 206010019851 Hepatotoxicity Diseases 0.000 description 5
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
• 206010060862 Prostate cancer Diseases 0.000 description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 230000000975 bioactive effect Effects 0.000 description 5
• 238000004422 calculation algorithm Methods 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 230000007783 downstream signaling Effects 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 231100000304 hepatotoxicity Toxicity 0.000 description 5
• 230000007686 hepatotoxicity Effects 0.000 description 5
• 210000004408 hybridoma Anatomy 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 239000000178 monomer Substances 0.000 description 5
• 230000009871 nonspecific binding Effects 0.000 description 5
• 230000008929 regeneration Effects 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 238000010361 transduction Methods 0.000 description 5
• 230000026683 transduction Effects 0.000 description 5
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 101710185679 CD276 antigen Proteins 0.000 description 4
• 102100038078 CD276 antigen Human genes 0.000 description 4
• 206010008342 Cervix carcinoma Diseases 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 108010021472 Fc gamma receptor IIB Proteins 0.000 description 4
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 4
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
• 102000008070 Interferon-gamma Human genes 0.000 description 4
• 108010002586 Interleukin-7 Proteins 0.000 description 4
• 208000008839 Kidney Neoplasms Diseases 0.000 description 4
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 4
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 4
• 206010038389 Renal cancer Diseases 0.000 description 4
• 206010041067 Small cell lung cancer Diseases 0.000 description 4
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 description 4
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
• 239000007825 activation reagent Substances 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 230000000735 allogeneic effect Effects 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 229950002916 avelumab Drugs 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 201000010881 cervical cancer Diseases 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 239000012228 culture supernatant Substances 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 206010017758 gastric cancer Diseases 0.000 description 4
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 4
• 239000002955 immunomodulating agent Substances 0.000 description 4
• 230000001506 immunosuppresive effect Effects 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 229960003130 interferon gamma Drugs 0.000 description 4
• 201000010982 kidney cancer Diseases 0.000 description 4
• 230000002147 killing effect Effects 0.000 description 4
• 238000004020 luminiscence type Methods 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 208000020816 lung neoplasm Diseases 0.000 description 4
• 238000001422 normality test Methods 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 238000002818 protein evolution Methods 0.000 description 4
• 238000011002 quantification Methods 0.000 description 4
• 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
• 208000000587 small cell lung carcinoma Diseases 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 229940054269 sodium pyruvate Drugs 0.000 description 4
• 201000011549 stomach cancer Diseases 0.000 description 4
• 229960005322 streptomycin Drugs 0.000 description 4
• 230000010474 transient expression Effects 0.000 description 4
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 3
• 239000012114 Alexa Fluor 647 Substances 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
• 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 3
• 238000008157 ELISA kit Methods 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 108700024394 Exon Proteins 0.000 description 3
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 239000012979 RPMI medium Substances 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 230000024932 T cell mediated immunity Effects 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 238000011319 anticancer therapy Methods 0.000 description 3
• 229940009098 aspartate Drugs 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 229930189065 blasticidin Natural products 0.000 description 3
• 229940022399 cancer vaccine Drugs 0.000 description 3
• 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000011198 co-culture assay Methods 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 239000013068 control sample Substances 0.000 description 3
• 239000003431 cross linking reagent Substances 0.000 description 3
• 230000016396 cytokine production Effects 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 238000007405 data analysis Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000000113 differential scanning calorimetry Methods 0.000 description 3
• 239000013613 expression plasmid Substances 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
• 208000005017 glioblastoma Diseases 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 235000004554 glutamine Nutrition 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
• 102000047410 human NFKB1 Human genes 0.000 description 3
• 230000003308 immunostimulating effect Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000004073 interleukin-2 production Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 201000007270 liver cancer Diseases 0.000 description 3
• 208000018191 liver inflammation Diseases 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 238000005457 optimization Methods 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 230000003285 pharmacodynamic effect Effects 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000003439 radiotherapeutic effect Effects 0.000 description 3
• 238000002864 sequence alignment Methods 0.000 description 3
• 238000009097 single-agent therapy Methods 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 239000013638 trimer Substances 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
• WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
• 239000012103 Alexa Fluor 488 Substances 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 108700031361 Brachyury Proteins 0.000 description 2
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 229910052693 Europium Inorganic materials 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 2
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
• 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 2
• 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
• 102000002227 Interferon Type I Human genes 0.000 description 2
• 108010014726 Interferon Type I Proteins 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000003812 Interleukin-15 Human genes 0.000 description 2
• 108090000172 Interleukin-15 Proteins 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 239000012661 PARP inhibitor Substances 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 229940123237 Taxane Drugs 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000003432 anti-folate effect Effects 0.000 description 2
• 229940127074 antifolate Drugs 0.000 description 2
• 230000030741 antigen processing and presentation Effects 0.000 description 2
• 239000003972 antineoplastic antibiotic Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000009697 arginine Nutrition 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 239000012911 assay medium Substances 0.000 description 2
• RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 150000001615 biotins Chemical class 0.000 description 2
• JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 2
• 201000008274 breast adenocarcinoma Diseases 0.000 description 2
• 239000006227 byproduct Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 239000008004 cell lysis buffer Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 238000002659 cell therapy Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical class N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 230000004186 co-expression Effects 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 208000037966 cold tumor Diseases 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 2
• 230000000139 costimulatory effect Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 229960003722 doxycycline Drugs 0.000 description 2
• XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
• 229950009791 durvalumab Drugs 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 229940096118 ella Drugs 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 239000004052 folic acid antagonist Substances 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 102000048362 human PDCD1 Human genes 0.000 description 2
• 150000007857 hydrazones Chemical class 0.000 description 2
• GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
• 229940097277 hygromycin b Drugs 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 229940027941 immunoglobulin g Drugs 0.000 description 2
• 210000005007 innate immune system Anatomy 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 108010074108 interleukin-21 Proteins 0.000 description 2
• XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 2
• 229940044173 iodine-125 Drugs 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
• OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 239000012516 mab select resin Substances 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 231100000682 maximum tolerated dose Toxicity 0.000 description 2
• 230000015654 memory Effects 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 238000000569 multi-angle light scattering Methods 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 229960001756 oxaliplatin Drugs 0.000 description 2
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical class O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 210000002741 palatine tonsil Anatomy 0.000 description 2
• 238000004091 panning Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 229960002621 pembrolizumab Drugs 0.000 description 2
• 238000009520 phase I clinical trial Methods 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 150000003057 platinum Chemical class 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 210000004986 primary T-cell Anatomy 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000011363 radioimmunotherapy Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 2
• 231100000847 severe hepatotoxicity Toxicity 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• GZCRRIHWUXGPOV-NJFSPNSNSA-N terbium-161 Chemical compound [161Tb] GZCRRIHWUXGPOV-NJFSPNSNSA-N 0.000 description 2
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 201000002510 thyroid cancer Diseases 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 108010082808 4-1BB Ligand Proteins 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 102100022464 5'-nucleotidase Human genes 0.000 description 1
• LLIANSAISVOLHR-GBCQHVBFSA-N 5-[(3as,4s,6ar)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LLIANSAISVOLHR-GBCQHVBFSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
• 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
• 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 229940125565 BMS-986016 Drugs 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
• 101100495352 Candida albicans CDR4 gene Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 102100025597 Caspase-4 Human genes 0.000 description 1
• 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 108010055196 EphA2 Receptor Proteins 0.000 description 1
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000933112 Homo sapiens Caspase-4 Proteins 0.000 description 1
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 1
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 1
• 101000956887 Homo sapiens Immunoglobulin lambda variable 2-8 Proteins 0.000 description 1
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
• 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010058683 Immobilized Proteins Proteins 0.000 description 1
• 102100038428 Immunoglobulin lambda variable 2-8 Human genes 0.000 description 1
• 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 1
• 101710085994 Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 102100030703 Interleukin-22 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000002698 KIR Receptors Human genes 0.000 description 1
• 108010043610 KIR Receptors Proteins 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• 229930064664 L-arginine Natural products 0.000 description 1
• 235000014852 L-arginine Nutrition 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• 101150030213 Lag3 gene Proteins 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 101100005714 Macaca fascicularis CD4 gene Proteins 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
• 101100207073 Mus musculus Tnfsf9 gene Proteins 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 108091005685 RIG-I-like receptors Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 102000000395 SH3 domains Human genes 0.000 description 1
• 108050008861 SH3 domains Proteins 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
• -1 TWEENTM Chemical class 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 208000000728 Thymus Neoplasms Diseases 0.000 description 1
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
• 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
• 229940127174 UCHT1 Drugs 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 229910052767 actinium Inorganic materials 0.000 description 1
• QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
• QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 1
• 229940125666 actinium-225 Drugs 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000006786 activation induced cell death Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 150000001294 alanine derivatives Chemical class 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000001512 anti-cytomegaloviral effect Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 229960003852 atezolizumab Drugs 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 210000003445 biliary tract Anatomy 0.000 description 1
• 208000020790 biliary tract neoplasm Diseases 0.000 description 1
• 238000013378 biophysical characterization Methods 0.000 description 1
• 108091006004 biotinylated proteins Proteins 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 238000002725 brachytherapy Methods 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 230000004611 cancer cell death Effects 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 190000008236 carboplatin Chemical class 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 238000003501 co-culture Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229960002465 dabrafenib Drugs 0.000 description 1
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000009615 deamination Effects 0.000 description 1
• 238000006481 deamination reaction Methods 0.000 description 1
• 229950008937 defactinib Drugs 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
• 229950005837 entinostat Drugs 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
• 229960003649 eribulin Drugs 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000002710 external beam radiation therapy Methods 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 201000003911 head and neck carcinoma Diseases 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 239000013628 high molecular weight specie Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 235000014304 histidine Nutrition 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 208000037967 hot tumor Diseases 0.000 description 1
• 102000050320 human TNFRSF4 Human genes 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000006054 immunological memory Effects 0.000 description 1
• 230000002480 immunoprotective effect Effects 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 238000012933 kinetic analysis Methods 0.000 description 1
• 239000000990 laser dye Substances 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 238000007169 ligase reaction Methods 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000013627 low molecular weight specie Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 238000002794 lymphocyte assay Methods 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Chemical class 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009437 off-target effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 244000309459 oncolytic virus Species 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 238000012514 protein characterization Methods 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 239000012217 radiopharmaceutical Substances 0.000 description 1
• 229940121896 radiopharmaceutical Drugs 0.000 description 1
• 230000002799 radiopharmaceutical effect Effects 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 239000012898 sample dilution Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000011519 second-line treatment Methods 0.000 description 1
• 238000002805 secondary assay Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 208000005893 serous cystadenoma Diseases 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 231100000057 systemic toxicity Toxicity 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 229960004066 trametinib Drugs 0.000 description 1
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000005829 trimerization reaction Methods 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 208000023747 urothelial carcinoma Diseases 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 229960000653 valrubicin Drugs 0.000 description 1
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1